- Home
- NHS vs ESPR Comparison
NHS vs ESPR Comparison
Compare NHS & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NHS
- ESPR
- Stock Information
- Founded
- NHS 2003
- ESPR 2008
- Country
- NHS United States
- ESPR United States
- Employees
- NHS N/A
- ESPR N/A
- Industry
- NHS Trusts Except Educational Religious and Charitable
- ESPR Biotechnology: Pharmaceutical Preparations
- Sector
- NHS Finance
- ESPR Health Care
- Exchange
- NHS Nasdaq
- ESPR Nasdaq
- Market Cap
- NHS 221.6M
- ESPR 208.1M
- IPO Year
- NHS N/A
- ESPR 2013
- Fundamental
- Price
- NHS $7.70
- ESPR $0.78
- Analyst Decision
- NHS
- ESPR Buy
- Analyst Count
- NHS 0
- ESPR 7
- Target Price
- NHS N/A
- ESPR $5.93
- AVG Volume (30 Days)
- NHS 111.8K
- ESPR 5.6M
- Earning Date
- NHS 01-01-0001
- ESPR 05-06-2025
- Dividend Yield
- NHS 13.44%
- ESPR N/A
- EPS Growth
- NHS N/A
- ESPR N/A
- EPS
- NHS N/A
- ESPR N/A
- Revenue
- NHS N/A
- ESPR $259,574,000.00
- Revenue This Year
- NHS N/A
- ESPR $5.70
- Revenue Next Year
- NHS N/A
- ESPR N/A
- P/E Ratio
- NHS N/A
- ESPR N/A
- Revenue Growth
- NHS N/A
- ESPR 12.99
- 52 Week Low
- NHS $6.95
- ESPR $0.82
- 52 Week High
- NHS $9.17
- ESPR $3.94
- Technical
- Relative Strength Index (RSI)
- NHS 59.96
- ESPR 31.61
- Support Level
- NHS $7.53
- ESPR $0.73
- Resistance Level
- NHS $7.64
- ESPR $1.11
- Average True Range (ATR)
- NHS 0.09
- ESPR 0.10
- MACD
- NHS 0.02
- ESPR 0.00
- Stochastic Oscillator
- NHS 90.74
- ESPR 13.34
About NHS Neuberger Berman High Yield Strategies Fund
Neuberger Berman High Yield Strategies Fund is closed-end management investment company. It seeks to achieve its investment objective by investing, under normal market conditions, a majority of its total assets in high yield debt securities of U.S. and foreign issuers.
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.